Clinical Trial Detail

NCT ID NCT02723006
Title Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Millennium Pharmaceuticals, Inc.



MLN2480 + Nivolumab

MLN1202 + Nivolumab

Ipilimumab + Nivolumab + Vedolizumab

Age Groups: adult

Additional content available in CKB BOOST